The Combined Relationship of Prescription Drug Monitoring Program Enactment and Medical Cannabis Laws with Chronic Pain-Related Healthcare Visits
- PMID: 39354252
- PMCID: PMC11968579
- DOI: 10.1007/s11606-024-09053-6
The Combined Relationship of Prescription Drug Monitoring Program Enactment and Medical Cannabis Laws with Chronic Pain-Related Healthcare Visits
Abstract
Background: U.S. state electronic prescription drug monitoring programs (PDMPs) are associated with reduced opioid dispensing among people with chronic pain and may impact use of other chronic pain treatments. In states with medical cannabis laws (MCLs), patients can use cannabis for chronic pain management, reducing their need for chronic-pain related treatment visits and moderating effects of PDMP laws.
Objective: Given high rates of chronic pain among Medicaid enrollees, we examined associations between PDMP enactment in the presence or absence of MCL on chronic pain-related outpatient and emergency department (ED) visits.
Design: We created annual cohorts of Medicaid enrollees with chronic pain diagnoses using national Medicaid claims data from 2002-2013 and 2016. Negative binomial hurdle models produced adjusted odds ratios (aOR) for the likelihood of any chronic pain-related outpatient or ED visit and incident rate ratios (IRR) for the rate of visits among patients with ≥ 1 visit.
Participants: Medicaid enrollees aged 18-64 years with chronic pain (N = 4,878,462).
Main measures: A 3-level state-year variable with the following categories: 1) no PDMP, 2) PDMP enactment in the absence of MCL, or 3) PDMP enactment in the presence of MCL. Healthcare codes for chronic pain-related outpatient and ED visits each year.
Key results: The sample was primarily female (67.2%), non-Hispanic White (51.2%), and ages 40-55 years (37.2%). Compared to no-PDMP states, PDMP enactment in the absence of MCL was not associated with chronic pain-related outpatient visits but PDMP enactment in the presence of MCL was associated with lower odds of chronic pain-related outpatient visits (aOR = 0.81, 95% CI:0.71-0.92). PDMP enactment was not associated with ED visits, irrespective of MCL.
Conclusions: During a period of PDMP and MCL expansion, our findings suggest treatment shifts for persons with chronic pain away from outpatient settings, potentially related to increased use of cannabis for chronic pain management.
Keywords: chronic pain; healthcare utilization; medical cannabis laws; prescription drug monitoring programs.
© 2024. The Author(s), under exclusive licence to Society of General Internal Medicine.
Conflict of interest statement
Declarations:. Conflicts of Interest:: KMK provides expert testimony for various law firms in the US. DSH receives funding from Syneos Health for an unrelated project on the measurement of opioid use disorder among patients with chronic pain.
References
-
- Yong RJ, Mullins PM, Bhattacharyya N. Prevalence of chronic pain among adults in the United States. Pain. 2022;163(2):e328-e332. 10.1097/j.pain.0000000000002291. - PubMed
-
- Oliveira CB, Maher CG, Franco MR, Kamper SJ, Williams CM, Silva FG, Pinto RZ. Co-occurrence of Chronic Musculoskeletal Pain and Cardiovascular Diseases: A systematic review with meta-analysis. Pain Med. 2020;21(6):1106-1121. 10.1093/pm/pnz217. - PubMed
-
- Feldman DE, Nahin RL. Disability among persons with chronic severe back pain: Results from a nationally representative population-based sample. J Pain. 2022;23(12):2144-2154. 10.1016/j.jpain.2022.07.016. - PubMed
-
- Gaskin DJ, Richard P. The economic costs of pain in the United States. J Pain. 2012;13(8):715-24. 10.1016/j.jpain.2012.03.009. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical